IIS-Fundación Jiménez Díaz, UAM, Av. Reyes Católicos, 2, 28040, Madrid, Spain.
Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain.
BMC Med. 2018 Feb 28;16(1):30. doi: 10.1186/s12916-018-1026-6.
Despite long-lasting HIV replication control, a significant proportion of elite controller (EC) patients may experience CD4 T-cell loss. Discovering perturbations in immunological parameters could help our understanding of the mechanisms that may be operating in those patients experiencing loss of immunological control.
A case-control study was performed to evaluate if alterations in different T-cell homeostatic parameters can predict CD4 T-cell loss in ECs by comparing data from EC patients showing significant CD4 decline (cases) and EC patients showing stable CD4 counts (controls). The partial least-squares-class modeling (PLS-CM) statistical methodology was employed to discriminate between the two groups of patients, and as a predictive model.
Herein, we show that among T-cell homeostatic alterations, lower levels of naïve and recent thymic emigrant subsets of CD8 cells and higher levels of effector and senescent subsets of CD8 cells as well as higher levels of exhaustion of CD4 cells, measured prior to CD4 T-cell loss, predict the loss of immunological control.
These data indicate that the parameters of T-cell homeostasis may identify those EC patients with a higher proclivity to CD4 T-cell loss. Our results may open new avenues for understanding the mechanisms underlying immunological progression despite HIV replication control, and eventually, for finding a functional cure through immune-based clinical trials.
尽管 HIV 复制得到长期控制,但仍有相当一部分精英控制者(EC)患者可能会出现 CD4 T 细胞损失。发现免疫参数的变化可能有助于我们理解那些免疫控制丧失患者的可能作用机制。
进行了一项病例对照研究,通过比较表现出显著 CD4 下降的 EC 患者(病例)和 CD4 计数稳定的 EC 患者(对照)的数据,评估不同 T 细胞稳态参数的改变是否可以预测 EC 中 CD4 T 细胞的损失。采用偏最小二乘分类建模(PLS-CM)统计方法来区分两组患者,并作为预测模型。
本研究表明,在 T 细胞稳态改变中,CD8 细胞的幼稚和近期胸腺迁出亚群水平较低,CD8 细胞的效应和衰老亚群水平较高,以及 CD4 细胞的耗竭水平较高,这些都可预测免疫控制的丧失。
这些数据表明,T 细胞稳态的参数可能可以识别出那些更容易发生 CD4 T 细胞损失的 EC 患者。我们的研究结果可能为理解尽管 HIV 复制得到控制但仍导致免疫进展的机制提供新的途径,并最终通过免疫为基础的临床试验找到功能性治愈方法。